Amgen Cuts Price of Cholesterol Drug Repatha Amid Trump's Call for Lower Drug Prices

Amgen has launched a direct-to-patient program called AmgenNow, which will offer its cholesterol medication Repatha at a reduced price of $239 per month, a 60% discount from the current US list price. The move follows the Trump administration's call to lower drug prices through direct-to-consumer pricing and international price benchmarking. GoodRX will also reduce its price for Repatha to match Amgen.

Amgen (NASDAQ: AMGN) has announced the launch of its direct-to-patient program, AmgenNow, which will offer its cholesterol medication Repatha at a reduced price of $239 per month. This move comes in response to the Trump administration's call to lower drug prices through direct-to-consumer pricing and international price benchmarking. The price reduction represents a 60% discount from the current US list price Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price^[1].

Repatha, a PCSK9 inhibitor, is used to reduce the risk of heart attacks and strokes in adults with established cardiovascular disease. The drug is also indicated for primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The reduced price will make the medication more accessible to patients, particularly those on Medicare, who often face high out-of-pocket costs Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price^[1].

GoodRX, a popular prescription discount service, will also reduce its price for Repatha to match Amgen's discounted price. This move is expected to further enhance affordability for patients and increase access to the medication. The new pricing structure is part of Amgen's ongoing efforts to address the significant public health issue of cardiovascular disease and reduce barriers to treatment Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price^[1].

Amgen's initiative follows a trend of pharmaceutical companies exploring direct-to-patient programs to lower drug costs. The company has been actively participating in the American Heart Association's Value in Healthcare Initiative and has been providing significant rebates to payers in exchange for improved patient access Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price^[1].

The launch of AmgenNow is set to commence in the coming months, with the exact timeline and availability of delivery systems to be announced soon. The program aims to provide a comprehensive suite of services to help patients and providers, including a $5 co-pay card for eligible commercially insured patients, insurance coverage support, and injection training Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price^[1].